Medical device firm NeuroPace beats Q2 revenue view, raises 2025 guidance
Overview
NeuroPace Inc Q2 revenue grows 22% yr/yr to $23.5 mln, beating estimates
Company raises full-year 2025 revenue guidance to $94-$98 mln
Gross margin improves to 77.1% driven by manufacturing efficiencies
Outlook
NeuroPace raises 2025 revenue guidance to $94 mln-$98 mln
Company increases 2025 gross margin guidance to 75%-76%
Result Drivers
RNS SYSTEM SALES - Revenue growth driven by increased sales of the RNS System
MANUFACTURING EFFICIENCIES - Strong gross margin of 77.1% attributed to manufacturing efficiencies and positive product mix
PROJECT CARE MOMENTUM - Increased contribution from Project CARE in Q2 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $23.52 mln | $23.10 mln (8 Analysts) |
Q2 EPS |
| -$0.26 |
|
Q2 Net Income |
| -$8.65 mln |
|
Q2 Gross Profit |
| $18.13 mln |
|
Q2 Income from Operations |
| -$6.82 mln |
|
Q2 Operating Expenses |
| $24.96 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Neuropace Inc is $17.00, about 47.7% above its August 11 closing price of $8.89
Press Release: ID:nGNX1fD17D
Related Articles
Applied Materials Q3 Earnings: AI Demand Soars, but Cautious Guidance Triggers After-Hours Selloff
TradingKey - Applied Materials, Inc. (NASDAQ: AMAT) announced its Q3 FY2025 earnings on August 14, 2025, after market close, reporting strong revenue fueled by AI-related semiconductor demand, which beat expectations. However, cautious Q4 guidance, including EPS below analyst estimates.jpg)
The Market Game of the Quantitative King: How Renaissance Technologies Locks in Excess Returns Amid the 2025 Turmoil
TradingKey - Founded by mathematician James Simons, Renaissance Technologies LLC is a global leader in quantitative investing, renowned for its data-driven, innovative approach. The firm eschews traditional fundamental analysis, relying instead on advanced mathematical models
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing..jpg)
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
